title: Trabectedin for the management of soft-tissue sarcoma.
abstract: Trabectedin is a new marine-derived compound that binds the DNA minor groove and interacts with proteins of the DNA-repair machinery. Trabectedin has shown promising single-agent activity in pretreated patients with soft-tissue sarcoma (STS) and ovarian and breast cancer; combination with various other chemotherapeutic drugs is feasible. Toxicities are mainly hematological and hepatic, with grade 3-4 neutropenia and thrombocytopenia observed in approximately 50 and 20% of patients, respectively, and grade 3-4 elevation of liver transaminases observed in 35-50% of patients treated with trabectedin. Trabectedin obtained regulatory approval by the EMEA and in other countries for the treatment of STS patients after failure of all available standard-of-care chemotherapy. Current research focuses on the identification of predictive factors for patients treated with trabectedin as well as the development of other combinations.
authors.affiliation: Unité de Jour d'Oncologie Médicale Multidisciplinaire, Hôpital Edouard Herriot, Lyon, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Boudou
authors.forename: Mathieu
authors.initials: M
authors.lastname: Baconnier
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
authors.forename: Catherine
authors.initials: C
authors.lastname: Lombard-Bohas
authors.forename: Philippe A
authors.initials: PA
authors.lastname: Cassier
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D018849:Controlled Clinical Trials as Topic; D004260:DNA Repair / Q000187:drug effects; D004149:Dioxoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D009503:Neutropenia / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D012509:Sarcoma / Q000188:drug therapy* / Q000503:physiopathology; D044005:Tetrahydroisoquinolines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D000077606:Trabectedin; D000637:Transaminases / Q000187:drug effects / Q000378:metabolism
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; D000637:Transaminases; D000077606:Trabectedin